On Feb. 18, 2026, Johnson & Johnson announced announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.

In building this facility, Johnson & Johnson continues to invest in cutting-edge manufacturing processes and in training to develop a workforce skilled in advanced technologies that are shaping the future of medicine. It will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development.

In building this facility, Johnson & Johnson continues to invest in cutting-edge manufacturing processes and in training to develop a workforce skilled in advanced technologies that are shaping the future of medicine. It will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development.